PTCT

PTC Therapeutics

PTCT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,834

Bullish sentiment (50-day avg)82%

Price to earnings ratio7.5

Market capitalization5.5B

Earnings per share-0.67

Dividend yield (TTM)—

Revenue (annual)1.7B

Net income (annual)682.6M

Social

What share of all stock conversation is about PTCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

May 8

PTC Therapeutics' Q1 2026 earnings beat profit expectations by 93.75%, with Sephience launch momentum driving record revenue of $273M.
The company raised its 2026 product revenue guidance to $750M-$850M, driven by Sephience launch momentum, Japan entry, and pipeline progress.
Analysts upgraded the stock to Buy, citing strong growth momentum, with Wells Fargo raising its target price from $86 to $95.

Generated by AI

Sentiment

Of the messages about PTCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +29.79	88.47% -3.21
Bearish	—	0% 0	0% -29.79	11.53% +3.21

Bullish· Sep 2

PTC Therapeutics, Inc. (PTCT) is expected to see a significant boost from its real product earnings.
The company's market capitalization of $28M is undervalued compared to fintech comps trading at x20.
Morgan Stanley has upgraded PTCT to an Overweight rating with a price target of $76.

Bearish· May 24

$PTCT faces significant risks to its guidance following recent news, with multiple downgrades and a decline in pre-market trading.
PTC Therapeutics has struggled with clinical trial setbacks, scrapped programs, and a failed study, leading to a 28% decline in the stock.
The company has undergone significant leadership changes, including the ousting of its CEO and the termination of its CFO, with the stock down 19.2% following the announcement of a workforce reduction.

Generated by AI

Topics

Of the messages about PTCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	47.06%	81.25%	64.45%
Technical Analysis	100%	5.88%	3.91%	13.09%
Analysts	0%	47.06%	14.84%	21.85%
Controversies	0%	0%	0%	0.1%
Earnings	0%	0%	0%	0.4%
Macro	0%	0%	0%	0.1%

Earnings· Feb 28

PTC Therapeutics reported Q4 earnings with total revenues of $86.3 million and a net loss of $48.3 million.
The company missed earnings per share (EPS) estimates by $0.60 and beat revenue estimates by $2.28 million.
PTC Therapeutics guided FY19 revenue below consensus estimates.

Analysts· Sep 18

PTC Therapeutics, Inc. ($PTCT) has been downgraded to Neutral or Sell by several analysts, with price targets lowered to $22, $26, $26, $26, $26, $26, $26, $26, $29, $30, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31,

Announcements· Dec 2

PTC Therapeutics, Inc. ($PTCT) entered into a global license and collaboration agreement with Novartis ($NVS) for PTC518 Huntington's disease program, with $1.0B upfront payment and up to $1.9B in development, regulatory, and sales milestones.
The agreement includes a 40% US profit share and double-digit tiered royalties on ex-US sales, with a total potential value of up to $2.9B.
PTC Therapeutics' stock price rose 18% in premarket trading after the announcement, with analysts calling the deal a "strong buy" for the company.

Technical Analysis· Apr 15

The MACD line for $PTCT is close to cutting the zero line, indicating a potential sell signal.
The stock has formed a huge block red bearish candlestick, making a rebound unlikely based on technicals.
If $PTCT breaches $9.70, it may be a good time to consider a long position for a HOD breakout, but anything else would be a high-risk trade.

Generated by AI

Community

Of the messages about PTCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	43.28%	50.34%
Newcomers	100%	100%	56.72%	49.66%

Regulars· May 5

$PTCT reported Phase 2 PIVOT-HD results showing PTC518 met its primary endpoint with significant HTT protein reduction and favorable safety.
Citi stated that PTC Therapeutics' announcement regarding PIVOT-HD study data "brought more confusion than answers," citing mixed blood Huntingtin reductions at week 12.
PTC stock slid on new data for Huntington’s drug $PTCT, with the stock price dropping to 39.97, and target prices of 40.91 and 41.03.

Newcomers· Sep 2

Newcomers are excited about the potential for PTC Therapeutics, Inc. (PTCT) to see a significant boost in its stock price due to its real product earnings.
The company's market capitalization and trading volume are being closely watched by investors, with some expecting a potential double in their investment returns.
Big players and smart money are taking notice of PTCT, with some anticipating a "REV story" and a potential float squeeze, which could lead to a significant increase in the stock's value.

Generated by AI

News

Cantor raises PTC Therapeutics stock price target on Fabry deal

7d agoInvesting.com

PTC Therapeutics completes ST-920 gene therapy acquisition

8d agoInvesting.com

PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease

PTC Therapeutics (PTCT) said late Monday it completed the acquisition of ST-920, a gene therapy for

8d agofinance.yahoo.com

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

8d agoYahoo Finance

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therapeutics, with the share price down 3.9% over the last session to $65.37 and weaker momentum over the past quarter. However, the 3-year total shareholder return of 173.3% and 5-year total shareholder return of 66.4% still reflect a materially stronger long-run...

10d agoYahoo Finance

PTC Therapeutics director Schmertzler sells $1.35m shares

11d agoInvesting.com

Also Discussed

Investors talking about PTCT also mention

#	Name	Attention
1	Sarepta Therapeutics, Inc.SRPT	0%-0.01
2	BioMarin Pharmaceutical IncBMRN	0%+0
3	Puma Biotechnology, Inc.PBYI	0%0
4	Neurocrine Biosciences, Inc.NBIX	0%new
5	Ionis Pharmaceuticals, Inc.IONS	0%new
6	Acadia Pharmaceuticals Inc.ACAD	0%+0
7	FOLD - Amicus Therapeutics, Inc.	——
8	Agios Pharmaceuticals, Inc.AGIO	0%0
9	RDUS - Radius Recycling, Inc.	——
10	Alnylam Pharmaceuticals, Inc.ALNY	0%0

PTC Therapeutics, Inc.

Healthcare
Biotechnology

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders. Its current portfolio includes treatments for conditions such as Duchenne muscular dystrophy, phenylketonuria, and aromatic L-amino acid decarboxylase deficiency, along with other rare neurological and metabolic diseases. The company also works on gene therapy and small-molecule programs designed to address serious unmet medical needs. PTC Therapeutics serves children and adults in the United States and international markets, and its commercial offerings are supported by a research and development pipeline aimed at expanding its rare disease franchise. Headquartered in Warren, New Jersey, PTC Therapeutics plays a specialized role in the biopharmaceutical market by concentrating on niche therapies for complex, underserved patient populations.

Website

Location

500 Warren Corporate Center Drive

Warren, NJ, 07059

United States

Social

What share of all stock conversation is about PTCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

May 8

PTC Therapeutics' Q1 2026 earnings beat profit expectations by 93.75%, with Sephience launch momentum driving record revenue of $273M.
The company raised its 2026 product revenue guidance to $750M-$850M, driven by Sephience launch momentum, Japan entry, and pipeline progress.
Analysts upgraded the stock to Buy, citing strong growth momentum, with Wells Fargo raising its target price from $86 to $95.

Generated by AI

Sentiment

Of the messages about PTCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +29.79	88.47% -3.21
Bearish	—	0% 0	0% -29.79	11.53% +3.21

Bullish· Sep 2

PTC Therapeutics, Inc. (PTCT) is expected to see a significant boost from its real product earnings.
The company's market capitalization of $28M is undervalued compared to fintech comps trading at x20.
Morgan Stanley has upgraded PTCT to an Overweight rating with a price target of $76.

Bearish· May 24

$PTCT faces significant risks to its guidance following recent news, with multiple downgrades and a decline in pre-market trading.
PTC Therapeutics has struggled with clinical trial setbacks, scrapped programs, and a failed study, leading to a 28% decline in the stock.
The company has undergone significant leadership changes, including the ousting of its CEO and the termination of its CFO, with the stock down 19.2% following the announcement of a workforce reduction.

Generated by AI

Topics

Of the messages about PTCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	47.06%	81.25%	64.45%
Technical Analysis	100%	5.88%	3.91%	13.09%
Analysts	0%	47.06%	14.84%	21.85%
Controversies	0%	0%	0%	0.1%
Earnings	0%	0%	0%	0.4%
Macro	0%	0%	0%	0.1%

Earnings· Feb 28

PTC Therapeutics reported Q4 earnings with total revenues of $86.3 million and a net loss of $48.3 million.
The company missed earnings per share (EPS) estimates by $0.60 and beat revenue estimates by $2.28 million.
PTC Therapeutics guided FY19 revenue below consensus estimates.

Analysts· Sep 18

PTC Therapeutics, Inc. ($PTCT) has been downgraded to Neutral or Sell by several analysts, with price targets lowered to $22, $26, $26, $26, $26, $26, $26, $26, $29, $30, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31, $31,

Announcements· Dec 2

PTC Therapeutics, Inc. ($PTCT) entered into a global license and collaboration agreement with Novartis ($NVS) for PTC518 Huntington's disease program, with $1.0B upfront payment and up to $1.9B in development, regulatory, and sales milestones.
The agreement includes a 40% US profit share and double-digit tiered royalties on ex-US sales, with a total potential value of up to $2.9B.
PTC Therapeutics' stock price rose 18% in premarket trading after the announcement, with analysts calling the deal a "strong buy" for the company.

Technical Analysis· Apr 15

The MACD line for $PTCT is close to cutting the zero line, indicating a potential sell signal.
The stock has formed a huge block red bearish candlestick, making a rebound unlikely based on technicals.
If $PTCT breaches $9.70, it may be a good time to consider a long position for a HOD breakout, but anything else would be a high-risk trade.

Generated by AI

Community

Of the messages about PTCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	43.28%	50.34%
Newcomers	100%	100%	56.72%	49.66%

Regulars· May 5

$PTCT reported Phase 2 PIVOT-HD results showing PTC518 met its primary endpoint with significant HTT protein reduction and favorable safety.
Citi stated that PTC Therapeutics' announcement regarding PIVOT-HD study data "brought more confusion than answers," citing mixed blood Huntingtin reductions at week 12.
PTC stock slid on new data for Huntington’s drug $PTCT, with the stock price dropping to 39.97, and target prices of 40.91 and 41.03.

Newcomers· Sep 2

Newcomers are excited about the potential for PTC Therapeutics, Inc. (PTCT) to see a significant boost in its stock price due to its real product earnings.
The company's market capitalization and trading volume are being closely watched by investors, with some expecting a potential double in their investment returns.
Big players and smart money are taking notice of PTCT, with some anticipating a "REV story" and a potential float squeeze, which could lead to a significant increase in the stock's value.

Generated by AI

PTC Therapeutics

Social

May 8

Bullish· Sep 2

Bearish· May 24

Earnings· Feb 28

Analysts· Sep 18

Announcements· Dec 2

Technical Analysis· Apr 15

Regulars· May 5

Newcomers· Sep 2

Cantor raises PTC Therapeutics stock price target on Fabry deal

PTC Therapeutics completes ST-920 gene therapy acquisition

PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

PTC Therapeutics director Schmertzler sells $1.35m shares

Also Discussed

PTC Therapeutics, Inc.

Company Information

Location

Cantor raises PTC Therapeutics stock price target on Fabry deal

PTC Therapeutics completes ST-920 gene therapy acquisition

PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

PTC Therapeutics director Schmertzler sells $1.35m shares

Also Discussed

Social

May 8

Bullish· Sep 2

Bearish· May 24

Earnings· Feb 28

Analysts· Sep 18

Announcements· Dec 2

Technical Analysis· Apr 15

Regulars· May 5

Newcomers· Sep 2